The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,834,377 in first-year total cost, median $457,460.
Most frequent study sections
- Special Emphasis Panel[ZTR1 CI-6 (02)]3
Most frequent institutions
- DUKE UNIVERSITY1
- UNIVERSITY OF CALIFORNIA, SAN DIEGO1
- VIRGINIA COMMONWEALTH UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2015 | Wee1 and HDAC inhibition in relapsed/refractory AML1UH2TR001373-01 | GRANT, STEVEN | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $938,670 | ZTR1 |
| 2015 | Evaluation of AZD9291 in Glioblastoma patients with activated EGFR1UH2TR001370-01 | KWATRA, MADAN MLESSER, GLENN J | DUKE UNIVERSITY, NC | $457,460 | ZTR1 |
| 2015 | Evaluation of a cathepsin S inhibitor as a potential drug for Chagas disease1UH2TR001369-01 | MCKERROW, JAMES H. | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $438,247 | ZTR1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.